Acknowledgements
RARE DISEASE
We thank the patients who took part in the study and their families, as well as the CHAMPION MG principal investigators, sub-investigators, and study coordinators. We also thank Sivani Paskaradevan (Alexion, AstraZeneca Rare Disease) for critical review of the manuscript; Kathleen Beasley (Alexion, AstraZeneca Rare Disease) for contributions to trial execution and data interpretation; Alice Zangrandi (Alexion, AstraZeneca Rare Disease) for clinical trial oversight; Ahmed Enayetallah, Sam Gokhale, Fanny O’Brien, Rodrigo Pavani, Nishi Rampal (all formerly of Alexion, AstraZeneca Rare Disease), and Nader Najafian (Alexion, AstraZeneca Rare Disease) for their contributions to the trial design, trial execution, and/or data interpretation. Medical writing support was provided by Mary Greenacre and Julie Ponting of Piper Medical Communications, funded by Alexion, AstraZeneca Rare Disease. A list of CHAMPION MG Study Group members is provided in the Supplementary Information.